PharmaGap Releases Compelling Results For GAP-107B8 From The U.S. National Cancer Institute

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

PharmaGap Inc. is pleased to announce results from the initial testing of its lead cancer drug GAP-107B8 by the U.S. National Cancer Institute (NCI).

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.